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A BS T R AC T
BACKGROUND

Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only
60% of patients are cured with R-CHOP. Polatuzumab vedotin is an antibody–drug
conjugate targeting CD79b, which is ubiquitously expressed on the surface of malignant B cells.

The authors’ full names, academic degrees, and affiliations are listed in the Appendix. Dr. Tilly can be contacted at
herve.tilly@chb.unicancer.fr or at Centre
Henri-Becquerel, Rue d’Amiens, CS 11516,
76038 Rouen Cedex 1, France.

METHODS

A list of investigators in the POLARIX trial is provided in the Supplementary Appendix, available at NEJM.org.

We conducted a double-blind, placebo-controlled, international phase 3 trial to
evaluate a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was
replaced with polatuzumab vedotin, as compared with standard R-CHOP, in patients with previously untreated intermediate-risk or high-risk DLBCL. Patients 18
to 80 years of age were randomly assigned in a 1:1 ratio to receive six cycles of
either pola-R-CHP or R-CHOP, plus two cycles of rituximab alone. The primary end
point was investigator-assessed progression-free survival. Secondary end points
included overall survival and safety.

Drs. Flowers and Salles contributed equally
to this article.
This article was published on December 14,
2021, at NEJM.org.
N Engl J Med 2022;386:351-63.
DOI: 10.1056/NEJMoa2115304
Copyright © 2021 Massachusetts Medical Society.

RESULTS

Overall, 879 patients underwent randomization: 440 were assigned to the polaR-CHP group and 439 to the R-CHOP group. After a median follow-up of 28.2
months, the percentage of patients surviving without progression was significantly
higher in the pola-R-CHP group than in the R-CHOP group (76.7% [95% confidence
interval (CI), 72.7 to 80.8] vs. 70.2% [95% CI, 65.8 to 74.6] at 2 years; stratified
hazard ratio for progression, relapse, or death, 0.73 by Cox regression; 95% CI,
0.57 to 0.95; P = 0.02). Overall survival at 2 years did not differ significantly between
the groups (88.7% [95% CI, 85.7 to 91.6] in the pola-R-CHP group and 88.6%
[95% CI, 85.6 to 91.6] in the R-CHOP group; hazard ratio for death, 0.94; 95% CI,
0.65 to 1.37; P = 0.75). The safety profile was similar in the two groups.
CONCLUSIONS

Among patients with previously untreated intermediate-risk or high-risk DLBCL,
the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP. (Funded by F. Hoffmann–
La Roche/Genentech; POLARIX ClinicalTrials.gov number, NCT03274492.)
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iffuse large B-cell lymphoma
(DLBCL) is the most common form of
lymphoma.1 The addition of rituximab,
an anti-CD20 monoclonal antibody, to the CHOP
regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone) has yielded substantial
improvement in patient outcomes.2,3 Although
most patients (depending on prognostic factors)
can be cured with rituximab plus CHOP (R-CHOP),
up to 40% of patients will have disease that is
refractory to this treatment or will have a relapse
after an initial response.4,5 To improve treatment
outcomes with R-CHOP, numerous approaches
have been attempted in randomized trials, including intensification of chemotherapy6-8 or rituximab
(by increasing the doses or the number of cycles
or by shortening the interval between cycles),9
the addition of maintenance therapy,10,11 the use
of a second-generation anti-CD20 monoclonal
antibody,12 or incorporation of novel agents.13,14
These trials have not shown a meaningful improvement in outcomes, and R-CHOP remains
the standard first-line treatment for DLBCL.4,15
CD79b is a subunit of a heterodimer transmembrane component of the B-cell antigen receptor involved in cell signaling and is ubiquitously expressed on the surface of mature B-cell
lymphomas, including DLBCL.16,17 Polatuzumab
vedotin is an antibody–drug conjugate composed
of an anti-CD79b monoclonal antibody18 conjugated by a protease-cleavable linker to monomethyl auristatin E, a potent microtubule inhibitor.16,19 Polatuzumab vedotin has shown efficacy
in patients with relapsed or refractory DLBCL,
both as a single agent (with an overall response
of 52%)20 and in combination with rituximab.21
In a recent randomized trial involving patients
with relapsed or refractory DLBCL, the addition
of polatuzumab vedotin to bendamustine and
rituximab resulted in significantly longer overall
survival than treatment with bendamustine and
rituximab alone.22
In a phase 1b–2 trial in which polatuzumab
vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone
(pola-R-CHP) was investigated as first-line therapy for DLBCL, 89% of the patients had an overall response and 77% had a complete response.
Vincristine was excluded from the regimen owing
to the risk of overlapping neurologic toxic effects
with polatuzumab vedotin.23 We conducted the
phase 3 POLARIX trial to evaluate the efficacy
n engl j med 386;4
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and safety of pola-R-CHP, as compared with
R-CHOP, in patients with previously untreated
DLBCL.

Me thods
Trial Conduct

The POLARIX trial is a randomized, double-blind,
placebo-controlled, international phase 3 trial.
The protocol, which is available with the full text
of this article at NEJM.org, was approved by the
institutional review board or ethics committee at
each participating institution. The trial was conducted in accordance with the Good Clinical
Practice guidelines of the International Council
for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use and the principles of the Declaration of Helsinki.24 All the patients provided written informed consent. The
trial was sponsored by F. Hoffmann–La Roche/
Genentech and was designed by the sponsor in
collaboration with the Lymphoma Study Association. An independent data and safety monitoring
committee reviewed safety data on a regular basis
during the conduct of the trial. The first draft of
the manuscript was written primarily by one
academic author and one author employed by the
sponsor; medical writing assistance was funded
by the sponsor. All the authors reviewed the data
and contributed to the preparation of the final
version of the manuscript. The authors vouch for
the completeness and accuracy of the data and
for the fidelity of the trial to the protocol and
statistical analysis plan.
Patients

Patients were eligible for inclusion if they were
18 to 80 years of age, had CD20-positive DLBCL,25
had not received previous treatment for lymphoma, had an Eastern Cooperative Oncology Group
performance status score of 0 to 2 (on a 5-point
scale, with higher numbers indicating greater
disability), had a baseline International Prognostic Index (IPI)26 score between 2 and 5 (on a 5-level
prognostic scale, with higher numbers indicating a poorer prognosis), and had adequate hematologic, renal, hepatic, and cardiac function,
regardless of the cell of origin or the presence of
rearrangements in MYC, BCL2, BCL6, or a combination of these. Key exclusion criteria were a history of indolent lymphoma, a contraindication to
any component of R-CHOP, previous receipt of
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anthracycline agents, and known central nervous
system (CNS) involvement. Details of the eligibility criteria and trial methods are provided in the
Supplementary Appendix, available at NEJM.org.
Randomization and Blinding

Eligible patients were randomly assigned in a 1:1
ratio to receive pola-R-CHP or R-CHOP. The doses
and treatment schedules used are described below and in further detail in the protocol. Randomization was stratified according to IPI score
(2 vs. 3 to 5), status with respect to bulky disease
(present [one or more lesions ≥7.5 cm in greatest
dimension] vs. absent), and geographic region
(Western Europe, the United States, Canada, and
Australia vs. Asia vs. rest of world). The investigator, sponsor, and patients were unaware of the
treatment assignments. Details of the randomization procedure and blinding are provided in
the protocol.
Treatment

Eight 21-day cycles of treatment were planned.
During the first six cycles, patients received either pola-R-CHP or R-CHOP. On day 1 of each
cycle, patients received either intravenous polatuzumab vedotin at a dose of 1.8 mg per kilogram of body weight and a placebo matching
intravenous vincristine (pola-R-CHP group) or a
placebo matching polatuzumab vedotin and intravenous vincristine at a dose of 1.4 mg per
square meter of body-surface area (maximum of
2 mg) (R-CHOP group), plus intravenous doses
of rituximab (375 mg per square meter), cyclophosphamide (750 mg per square meter), and
doxorubicin (50 mg per square meter). All the
patients also received oral prednisone at a dose
of 100 mg once daily on days 1 through 5 of each
of the first six cycles. During cycles 7 and 8,
patients in both groups received rituximab monotherapy at a dose of 375 mg per square meter.
CNS prophylaxis with intrathecal chemotherapy was permitted, in accordance with institutional practice guidelines. The use of granulocyte colony-stimulating factor (G-CSF) was
required during the first six cycles of treatment
for primary prophylaxis against neutropenia.
The administration of consolidative radiotherapy
to initial sites of bulky disease or extranodal
sites was permitted at the discretion of the investigator. In such cases, radiotherapy had to be
planned before randomization and was given
n engl j med 386;4

after end-of-treatment assessments, as described
in the Supplementary Appendix. Details of the
management of dose interruptions, dose modifications, discontinuations of polatuzumab vedotin and vincristine, and any other permitted treatments are provided in the protocol.
End Points and Assessments

The primary efficacy end point was investigatorassessed progression-free survival as calculated
in a time-to-event analysis, in which investigatorassessed disease progression and disease relapse
or death from any cause were counted as events.
Key secondary end points, which were examined
hierarchically,27 were investigator-assessed eventfree survival (as assessed in a time-to-event analysis, in which an event was defined as investigator-assessed disease progression or relapse, death
from any cause, initiation of any treatment for
lymphoma that was not specified in the protocol, or biopsy-confirmed residual disease after
treatment completion); positron-emission tomography and computed tomography (PET-CT)–based
complete response at the end of treatment as
determined by blinded independent central review; and overall survival. Details regarding the
hierarchical testing are described further in the
Supplementary Appendix. An additional secondary end point, which was not subject to hypothesis testing, was investigator-assessed disease-free
survival as evaluated in a time-to-event analysis.
The analysis of disease-free survival included
patients who had a best overall response of complete response and was therefore based on a
subgroup of patients that was defined after randomization. Details of the methods regarding
additional secondary and exploratory end points
are provided in the protocol. The primary safety
objective was to compare the incidence of adverse events in the two treatment groups. Adverse events were coded according to the Medical
Dictionary for Regulatory Activities, version 24.0, and
graded according to the National Cancer Institute
Common Terminology Criteria for Adverse Events,
version 4.0.
Lugano classification response criteria for lymphoma28 were used by the investigators to perform tumor assessments, as well as by the independent central review committee to evaluate
end-of-treatment response on the basis of PET-CT.
CT and PET-CT were required at baseline and at
treatment completion; CT, PET-CT, or both were
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planned after cycle 4 and during surveillance
(i.e., every 6 months for the next 24 months, then
every 12 months for the next 36 months). Cell-oforigin assessment, immunohistochemical analysis of BCL2 and MYC protein expression, and
fluorescence in situ hybridization to detect MYC,
BCL2, and BCL6 rearrangements were performed
at central laboratories (see the Supplementary
Appendix).

For patients who had no tumor assessment after
the baseline assessment or who had postbaseline assessment results that could not be evaluated for response, progression-free survival data
were censored at the date of randomization. All
P values are two-sided and are presented only for
end points that were tested in a hierarchical manner. The proportional-hazards assumption for
progression-free survival was evaluated with the
use of the method proposed by Grambsch and
Statistical Analysis
Therneau,29 and no evidence suggested violation
With the exception of the analysis of investigator- of the proportionality assumption. Detailed staassessed disease-free survival (described above), tistical methods are described in the statistical
the efficacy analyses were performed in the in- analysis plan and in the Supplementary Appendix.
tention-to-treat population, which included all
patients who underwent randomization. The safeR e sult s
ty analysis population included all patients who
received at least one dose of any of the trial drugs. Patients
The primary analyses reported here were per- Overall, 1063 patients were screened for eligibilformed after 228 events (disease progression, re- ity. Between November 14, 2017, and June 27,
lapse, or death) had occurred and all patients had 2019, a total of 879 patients underwent randombeen enrolled in the trial for at least 24 months. ization: 440 were assigned to the pola-R-CHP
These analyses included the primary analyses of group and 439 to the R-CHOP group (the intenprogression-free survival, event-free survival, and tion-to-treat population) (Fig. 1). The safety popcomplete response, as well as the interim analy- ulation included 435 patients in the pola-R-CHP
sis of overall survival.
group and 438 patients in the R-CHOP group.
For the primary efficacy end point of investi- The demographic and clinical characteristics of
gator-assessed progression-free survival, under the two groups were similar at baseline (Table 1
the assumption of a hazard ratio of 0.69, we esti- and Table S1 in the Supplementary Appendix).
mated that a sample of 875 patients would result The median age of the overall patient population
in a total of 228 events. This would provide the was 65 years (range, 19 to 80). Stratification factrial with 80% power at a one-sided (2.5%) sig- tors (IPI score, presence or absence of bulky disnificance level (or equivalently, a two-sided [5.0%] ease, and geographic region) and centrally evalusignificance level) to detect a risk of disease ated subtypes of DLBCL were balanced between
progression, relapse, or death that was lower by the two groups. The median time between diagat least 23% (the minimum detectable differ- nosis, which was defined by the date of biopsy,
ence; hazard ratio, 0.77) with pola-R-CHP than and the initiation of treatment was similar in the
with R-CHOP. The null hypothesis would be re- two groups (26 days in the pola-R-CHP group
jected if the one-sided P value from a log-rank and 27 days in the R-CHOP group) (Table 1).
test was less than 0.025, with the conclusion that
progression-free survival was higher among pa- Treatment Exposure
tients who received pola-R-CHP than among Most of the patients received all six doses of the
those who received R-CHOP. The Kaplan–Meier active agents of polatuzumab vedotin or vincrismethod was used to estimate progression-free tine (91.7% and 88.5% in the pola-R-CHP and
survival in each treatment group. Estimates of R-CHOP groups, respectively); 88.0% and 85.9%
the treatment effect were expressed as hazard of the patients in the pola-R-CHP and R-CHOP
ratios and corresponding 95% confidence inter- groups, respectively, received all eight cycles of
vals and were derived with the use of a stratified treatment (Fig. 1). The median relative dose
Cox proportional-hazards analysis. In patients intensities (the proportions of administered doses
who were progression-free at the time of data relative to planned doses) of rituximab, doxorucutoff, progression-free survival data were cen- bicin, and cyclophosphamide were greater than
sored at the date of the last disease assessment. 99% in both treatment groups.
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1063 Patients were assessed for eligibility

184 Were not eligible

879 Underwent randomization

440 Were assigned to receive pola-R-CHP

439 Were assigned to receive R-CHOP

62 Did not complete all planned
treatment
2 Did not receive any trial
drugs
60 Discontinued treatment
early
21 Had adverse event
17 Had progressive
disease
22 Had other reason

53 Did not complete all planned
treatment
4 Did not receive any trial
drugs
49 Discontinued treatment
early
20 Had adverse event
12 Had progressive
disease
17 Had other reason

387 Completed treatment

377 Completed treatment

374 Remain in trial follow-up
66 Discontinued trial

363 Remain in trial follow-up
76 Discontinued trial

Figure 1. Enrollment, Randomization, and Follow-up.
The most common eligibility criteria that patients did not meet were an International Prognostic Index score between 2 and 5 (23 patients), the availability of archival or freshly collected tumor tissue before trial enrollment (22
patients), a signed written informed consent form (19 patients), and the presence of previously untreated CD20positive diffuse large B-cell lymphoma (19 patients). In the pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone) group, the reasons for not receiving treatment were physician decision
(2 patients), patient withdrawal (1 patient), and exclusion criteria identified (1 patient). In the R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone) group, the reasons for not receiving treatment were
patient withdrawal and other cancer identified (1 patient each).

In total, 11 patients (2.5%) in the pola-R-CHP
group and 18 patients (4.1%) in the R-CHOP
group received preplanned radiotherapy after
completion of the trial treatment, as allowed according to the protocol. A total of 72 patients
(16.4%) in the pola-R-CHP group and 86 patients
(19.6%) in the R-CHOP group received CNS prophylaxis (Table S2).

to 43.4), the risk of progression, relapse, or
death was significantly lower in the pola-R-CHP
group than in the R-CHOP group (stratified hazard ratio, 0.73; 95% confidence interval [CI], 0.57
to 0.95; P = 0.02) (Table 2 and Fig. 2A). Milestone
analysis showed that the percentage of patients
surviving without progression at 2 years was 6.5
percentage points higher in the pola-R-CHP group
than in the R-CHOP group (76.7% [95% CI, 72.7
Efficacy
to 80.8] vs. 70.2% [95% CI, 65.8 to 74.6]).
Primary End Point
The results of an exploratory subgroup analyAt the time of data cutoff (June 28, 2021), after sis of progression-free survival varied according
a median follow-up of 28.2 months (range, 0.1 to demographic and disease characteristics. Non engl j med 386;4
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Table 1. Demographic and Clinical Characteristics at Baseline (Intention-to-Treat Population).*
Characteristic

Pola-R-CHP
(N = 440)

R-CHOP
(N = 439)

Median age (range) — yr

65 (19–80)

66 (19–80)

Age category — no. (%)
≤60 yr

140 (31.8)

131 (29.8)

>60 yr

300 (68.2)

308 (70.2)

201 (45.7)

205 (46.7)

Female sex — no. (%)
Geographic region — no. (%)†
Western Europe, United States, Canada, and Australia

302 (68.6)

301 (68.6)

Asia

81 (18.4)

79 (18.0)

Rest of world

57 (13.0)

59 (13.4)

Ann Arbor stage — no. (%)‡
I or II

47 (10.7)

52 (11.8)

393 (89.3)

387 (88.2)

0 or 1

227 (51.6)

226 (51.5)

≥2

213 (48.4)

213 (48.5)

193 (43.9)

192 (43.7)

374 (85.0)

363 (82.7)

66 (15.0)

75 (17.1)

III or IV
No. of extranodal sites — no. (%)

Bulky disease — no. (%)†§
ECOG performance status score — no. (%)¶
0 or 1
2
Lactate dehydrogenase level — no. (%)‖
Normal

146 (33.2)

154 (35.1)

Elevated

291 (66.1)

284 (64.7)

IPI score — no. (%)†**
2

167 (38.0)

167 (38.0)

3 to 5

273 (62.0)

272 (62.0)

26 (16.0–37.5)

27 (19.0–41.0)

Germinal-center B-cell–like subtype

184/330 (55.8)

168/338 (49.7)

Activated B-cell–like subtype

102/330 (30.9)

119/338 (35.2)

Median time from initial diagnosis to treatment initiation (IQR) — days
Cell of origin — no./total no. (%)††

Unclassified
Double-expressor lymphoma — no./total no. (%)††
Double-hit or triple-hit lymphoma — no./total no. (%)††

44/330 (13.3)

51/338 (15.1)

139/362 (38.4)

151/366 (41.3)

26/331 (7.9)

19/334 (5.7)

*	A complete list of the demographic and clinical characteristics at baseline is provided in Table S8. IQR denotes interquartile range; polaR-CHP polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone; and R-CHOP rituximab, cyclophosphamide,
doxorubicin, vincristine, and prednisone.
†	This variable was a stratification factor.
‡	Stages range from I to IV, with higher stages indicating more extensive disease.
§	Bulky disease was defined as the presence of one or more lesions that were 7.5 cm or larger in greatest dimension.
¶	Patients were to have a baseline Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 (on a 5-point scale, with
higher numbers indicating greater disability). ECOG performance status was not reported for 1 patient in the R-CHOP group.
‖	The lactate dehydrogenase level was not reported for 3 patients in the pola-R-CHP group and for 1 patient in the R-CHOP group.
**	An International Prognostic Index (IPI) score indicates low (0 or 1), low–intermediate (2), high–intermediate (3), or high (4 or 5) risk of
a poor outcome on the basis of a scoring system that gives one point for each of the following risk factors: age older than 60 years, 1 or
more extranodal areas of disease, an ECOG performance status score of 2 or higher, a lactate dehydrogenase level above the upper limit
of the normal range, and Ann Arbor stage III or IV disease.
††	Testing was performed at a central laboratory. Assessments of the cell-of-origin subtype were performed with the use of the NanoString
Lymph2Cx assay. Immunohistochemical analysis of MYC and BCL2 protein expression was performed for the assessment of doubleexpressor lymphoma. Tests for the presence of rearrangements in MYC, BCL2, BCL6, or a combination of these were performed for the
assessment of double-hit and triple-hit lymphoma. Percentages are based on the population of patients who had centrally reported results; patients who did not have baseline tumor-tissue samples or who had test failures were not included.
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table subgroups that did not show a clear benefit
with pola-R-CHP included patients 60 years of age
or younger, patients with the germinal-center
B-cell–like subtype of DLBCL, patients who had
bulky disease, and patients who had lower IPI
scores (Fig. S1).
Secondary End Points

The analysis of investigator-assessed event-free
survival showed that the relative risk of events
was lower in the pola-R-CHP group than in the
R-CHOP group (2-year event-free survival, 75.6%
[95% CI, 71.5 to 79.7] and 69.4% [95% CI, 65.0
to 73.8%], respectively; hazard ratio for event or
death, 0.75; 95% CI, 0.58 to 0.96; P = 0.02) (Table 2 and Fig. 2B). The percentage of patients
who had a complete response at the end of treatment, as determined by blinded central review,
did not differ significantly between the two groups
(78.0% in the pola-R-CHP group and 74.0% in
the R-CHOP group; P = 0.16). However, the analysis of investigator-assessed disease-free survival
indicated that patients who received pola-R-CHP
and had a complete response as the best response (Table S3) were more likely to have persistence of remission than those who received
R-CHOP and had a complete response (hazard
ratio for relapse or death, 0.70; 95% CI, 0.50 to
0.98) (Table 2 and Fig. 2C). Overall survival did
not differ significantly between the groups (Table 2 and Fig. 2D). Disease progression or relapse
with CNS involvement was reported in 13 patients (3.0%) in the pola-R-CHP group and in 12
patients (2.7%) in the R-CHOP group (Table S2).
Subsequent Treatment for Lymphoma

At the time of data cutoff, 99 of the 440 patients
(22.5%) in the pola-R-CHP group and 133 of the
439 patients (30.3%) in the R-CHOP group had
received at least one subsequent course of therapy for lymphoma that was not specified in the
protocol (Table S4). The percentage of patients
receiving radiotherapy (preplanned or unplanned)
was lower in the pola-R-CHP group than in the
R-CHOP group (9.3% vs. 13.0%), as was the percentage of patients receiving systemic therapy
(17.0% vs. 23.5%), including stem-cell transplantation (3.9% vs. 7.1%) and chimeric antigen receptor (CAR) T-cell therapy (2.0% vs. 3.6%). After
disease progression, unblinding was permitted
for individual patients, and 8 patients (all in the
R-CHOP group) received polatuzumab vedotin as
part of a subsequent therapy.
n engl j med 386;4

Safety

The overall safety profile was generally similar
in the pola-R-CHP and R-CHOP groups, with
mostly similar types and incidences of adverse
events of both any grade and grade 3 or 4 reported
in the two groups (Table 3). No new safety signals were detected, and the safety profile of
pola-R-CHP was consistent with the known safety
profiles of the individual drugs.
The most common adverse events of grade 3
or 4 were neutropenia (28.3% in the pola-R-CHP
group and 30.8% in the R-CHOP group), febrile
neutropenia (13.8% and 8.0%, respectively), and
anemia (12.0% and 8.4%, respectively). Although
the incidence of febrile neutropenia was higher
among patients who received pola-R-CHP than
among those who received R-CHOP, the percentages of patients who had infections of grade 3
or 4 were similar (15.2% in the pola-R-CHP group
and 12.6% in the R-CHOP group), as were the
percentages of patients who discontinued at least
one of the drugs in the trial regimen (2.1% and
2.3%, respectively) or had dose reductions (1.8%
and 2.5%, respectively) because of either infections or neutropenia. Primary prophylaxis with
G-CSF was reported in 90.1% of the patients in
the pola-R-CHP group and in 93.2% of the patients in the R-CHOP group. Serious adverse
events were reported in 34.0% of the patients
who received pola-R-CHP and in 30.6% of the
patients who received R-CHOP (Table 3). Adverse events that resulted in death (i.e., adverse
events of grade 5) were reported in 13 patients
in the pola-R-CHP group and in 10 patients in
the R-CHOP group; these events were primarily
related to infections (pneumonia in 4 patients
and 3 patients, respectively, and sepsis in 1 patient and 3 patients, respectively) (Table S5).
Overall, 27 patients (6.2%) in the pola-R-CHP
group and 29 patients (6.6%) in the R-CHOP
group had adverse events that led to discontinuation of at least one of the drugs in the trial
regimen. Among these patients, 19 (4.4%) in the
pola-R-CHP group discontinued polatuzumab
vedotin because of adverse events, and 22 (5.0%)
in the R-CHOP group discontinued vincristine
because of adverse events; both drugs were mainly associated with neurologic events. Dose reductions of a trial drug owing to an adverse event
occurred in 9.2% of the patients who received
pola-R-CHP and in 13.0% of those who received
R-CHOP.
The incidence of peripheral neuropathy did
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Table 2. Efficacy (Intention-to-Treat Population).
Variable

Pola-R-CHP
(N = 440)

R-CHOP
(N = 439)

Hazard Ratio
(95% CI)

P Value

107 (24.3)

134 (30.5)

0.73 (0.57–0.95)

0.02

19

20

0.75 (0.58–0.96)

0.02

0.94 (0.65–1.37)

0.75

Progression-free survival*
Patients who died or had progression or relapse — no. (%)
Earliest event — no.
Death

88

114

Estimate at 1 year (95% CI) — %

Progression or relapse

83.9 (80.4–87.4)

79.8 (75.9–83.6)

Estimate at 2 years (95% CI) — %

76.7 (72.7–80.8)

70.2 (65.8–74.6)

112 (25.5)

138 (31.4)

Event-free survival*
Patients who died, had progression or relapse, or had
other events — no. (%)†
Earliest event — no.
Death

18

20

Progression or relapse

86

106

Other†

8

12

75.6 (71.5–79.7)

69.4 (65.0–73.8)

Overall response — no. (%)

376 (85.5)

368 (83.8)

Complete response

343 (78.0)

325 (74.0)

33 (7.5)

43 (9.8)

8 (1.8)

6 (1.4)

Progressive disease — no. (%)

22 (5.0)

28 (6.4)

Not evaluated or data missing — no. (%)

34 (7.7)

37 (8.4)

53 (12.0)

57 (13.0)

88.7 (85.7–91.6)

88.6 (85.6–91.6)

Estimate at 2 years (95% CI) — %
Response status at treatment completion‡

Partial response
Stable disease — no. (%)

Overall survival
Patients who died — no. (%)
Estimate at 2 years (95% CI) — %
Disease-free survival§
No. of patients who could be evaluated¶

381

363

Patients who died or had relapse — no. (%)

62 (16.3)

79 (21.8)

0.70 (0.50–0.98)

Earliest event — no.
Death

8

13

Relapse

54

66

*	Events of progression or relapse were assessed by the investigator.
†	Other events are subsequent therapy for lymphoma or biopsy-confirmed residual disease after treatment.
‡	Response was assessed by an independent central review committee.
§	Events of relapse were assessed by the investigator.
¶	Patients who had a best response of complete response at any time during the trial could be evaluated for disease-free survival; see Table S3.

not differ significantly between the treatment
groups (Table S6). Peripheral neuropathy of any
grade was reported in 52.9% of the patients who
received pola-R-CHP and in 53.9% of those who
received R-CHOP, and peripheral neuropathy of
grade 2 or higher was reported in 13.8% and
16.7% of the patients, respectively. The median
358
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time to the onset of any neuropathy was 2.3
months in the pola-R-CHP group and 1.9 months
in the R-CHOP group; the median time to resolution of any neuropathy was 4.0 months and
4.6 months, respectively. Very few patients discontinued any treatment because of peripheral
neuropathy (0.2% in the pola-R-CHP group and
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Figure 2. Kaplan–Meier Estimates of Efficacy End Points.
In the analysis of investigator-assessed progression-free survival, investigator-assessed disease progression and disease relapse or death
from any cause were counted as events. In the analysis of investigator-assessed event-free survival, an event was defined as investigatorassessed disease progression or relapse, death from any cause, initiation of any antilymphoma treatment that was not specified in the
protocol, or biopsy-confirmed residual disease after treatment completion. In the analysis of investigator-assessed disease-free survival,
investigator-assessed disease relapse or death from any cause were counted as events. Tick marks indicate censored data. NE denotes
not able to be evaluated.

0.9% in the R-CHOP group). The percentage of
patients who had peripheral neuropathy that led
to dose reduction was lower among those who
received polatuzumab vedotin than among those
who received vincristine (4.4% vs. 8.0%).

with previously untreated DLBCL. In this population of patients who had either intermediaterisk or high-risk disease, in which approximately
one third of the patients had activated B-cell–like
subtype DLBCL and almost two thirds had a
baseline IPI score between 3 and 5, treatment
with pola-R-CHP resulted in a risk of disease proDiscussion
gression, relapse, or death that was 27% lower
Treatment with pola-R-CHP showed a significant (stratified hazard ratio, 0.73; 95% CI, 0.57 to
progression-free survival benefit over the com- 0.95; P = 0.02) than that with R-CHOP. Progresmonly prescribed regimen R-CHOP in patients sion-free survival at 2 years was 76.7% in the
n engl j med 386;4
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Table 3. Adverse Events during the Treatment Period (Safety Population).*
Pola-R-CHP
(N = 435)

Adverse Event

Any Grade

R-CHOP
(N = 438)

Grade 3 or 4

Any Grade

Grade 3 or 4

number of patients (percent)
Peripheral neuropathy†

230 (52.9)

7 (1.6)

236 (53.9)

5 (1.1)

Nausea

181 (41.6)

5 (1.1)

161 (36.8)

2 (0.5)

Neutropenia

134 (30.8)

123 (28.3)

143 (32.6)

135 (30.8)

Diarrhea

134 (30.8)

17 (3.9)

88 (20.1)

8 (1.8)

Anemia

125 (28.7)

52 (12.0)

114 (26.0)

37 (8.4)

Constipation

125 (28.7)

5 (1.1)

127 (29.0)

1 (0.2)

Fatigue

112 (25.7)

4 (0.9)

116 (26.5)

11 (2.5)

Alopecia

106 (24.4)

0

105 (24.0)

1 (0.2)

Decreased appetite

71 (16.3)

5 (1.1)

62 (14.2)

3 (0.7)

Pyrexia

68 (15.6)

6 (1.4)

55 (12.6)

0

Vomiting

65 (14.9)

5 (1.1)

63 (14.4)

3 (0.7)

Febrile neutropenia

62 (14.3)

60 (13.8)

35 (8.0)

35 (8.0)

Headache

56 (12.9)

1 (0.2)

57 (13.0)

4 (0.9)

Cough

56 (12.9)

0

53 (12.1)

0

Decreased weight

55 (12.6)

4 (0.9)

52 (11.9)

1 (0.2)

Asthenia

53 (12.2)

7 (1.6)

53 (12.1)

2 (0.5)

Dysgeusia

49 (11.3)

0

57 (13.0)

0

*	Shown are the most common adverse events, which were defined as adverse events of any grade that occurred in at
least 12% of the patients in either treatment group. These adverse events are Medical Dictionary for Regulatory Activities,
version 24.0, preferred terms. Adverse events of any grade were reported in 426 patients (97.9%) in the pola-R-CHP group
and in 431 patients (98.4%) in the R-CHOP group; adverse events of grade 3 or higher in 264 (60.7%) and 262 (59.8%),
respectively; serious adverse events in 148 (34.0%) and 134 (30.6%), respectively; and adverse events of grade 5 in 13
(3.0%) and 10 (2.3%), respectively.
†	Peripheral neuropathy includes the following preferred terms from the system organ class of peripheral neuropathy:
peripheral neuropathy, peripheral sensory neuropathy, paresthesia, hypoesthesia, polyneuropathy, peripheral motor
neuropathy, dysesthesia, neuralgia, peripheral sensorimotor neuropathy, hypotonia, hyporeflexia, neuromyopathy, ear
paresthesia, peroneal nerve palsy, and skin burning sensation.

pola-R-CHP group, as compared with 70.2% in
the R-CHOP group.
Although this trial was not designed or powered to compare progression-free survival in
patient subgroups, the observed heterogeneity in
the treatment effect of pola-R-CHP across subgroups needs to be assessed in future trials.
Because CD79b is ubiquitously expressed on the
surface of mature B-cell lymphoid cancers, it is
expected that pola-R-CHP would be active in
mature B-cell lymphomas such as DLBCL and its
subtypes, including newly identified genetic subgroups.30-33 In our trial, point estimates that
suggested a benefit with pola-R-CHP among the
various patient subgroups evaluated were observed
in patients older than 60 years of age, in patients
360
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who had an IPI score between 3 and 5, and in
patients with the activated B-cell–like subtype of
DLBCL. Conversely, subgroups that did not show
a clear benefit were patients 60 years of age or
younger, those who had lower IPI scores, those
who had bulky disease, and those who had the
germinal-center B-cell–like subtype of DLBCL.
Among the key secondary end points, eventfree survival was significantly higher with polaR-CHP than with R-CHOP, and although the
percentage of patients who had a complete response did not differ significantly between the
groups, remissions appeared to be more durable
with pola-R-CHP than with R-CHOP. The median follow-up in this trial was 28.2 months, which
was not long enough to observe any effect of the
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progression-free survival benefit on overall survival. However, other studies have indicated that
progression-free survival and 2-year event-free
survival are often surrogates for overall survival
in patients with DLBCL.34-36 The lack of a significant difference between the two groups in
overall survival in our trial may also be explained
by the advent of new, effective treatments for relapsed or refractory DLBCL in recent years.
The relatively short follow-up provides limited
data confirming the expected plateau in the
progression-free survival curve. DLBCL is characterized by an early risk of relapse followed by
a distinct plateau in the survival curve that indicates a high probability of cure. Late relapses are
unusual. On the basis of previous treatment results,34-36 it is expected that the remissions that
have lasted at least 2 years will be durable. The
data from this trial do not yet confirm that the
remissions associated with pola-R-CHP treatment will be durable. Whether such a conclusion
can be drawn can be determined only with longer follow-up.
In this double-blind trial, drug delivery was
not impeded by the replacement of vincristine
with polatuzumab vedotin. The delivery of rituximab, doxorubicin, and cyclophosphamide was
maintained, with median relative dose intensities of greater than 99% in both treatment groups.
Moreover, the percentage of patients who received
all the planned doses of polatuzumab vedotin
was slightly higher than the percentage who received all the planned doses of vincristine (91.7%
in the pola-R-CHP group and 88.5% in the R-CHOP
group), and fewer patients in the pola-R-CHP
group than in the R-CHOP group had adverse
events that led to dose reductions.
The occurrence of peripheral neuropathy is
expected in patients treated with antibody–drug
conjugates containing monomethyl auristatin E
and has been described in a study of single-agent
polatuzumab vedotin20 and in studies of polatuzumab vedotin in combination with other
agents.21-23 In this trial, the majority of cases of

peripheral neuropathy were grade 1. Moreover,
the incidence and severity of peripheral neuropathy were similar in the two treatment groups.
These results are similar to those observed in
the ECHELON-2 trial, in which another antibody–
drug conjugate combination — brentuximab
vedotin with cyclophosphamide, doxorubicin,
and prednisone — was compared with CHOP in
patients with T-cell lymphoma.37 Although the
incidence of febrile neutropenia was higher
among patients who received pola-R-CHP than
among those who received R-CHOP in our trial
(14.3% vs. 8.0%), this finding did not translate
into a higher overall incidence of infection,
treatment discontinuation, or dose reductions
and was similar to the percentages reported in
recent R-CHOP trials (9.0% to 15.2%).12-14
Several groups of patients were not included
in the current trial: those with lymphoma arising
from previously diagnosed indolent lymphoma,
those with a primary mediastinal lymphoma,
and those older than 80 years of age. A phase 3
trial investigating an age-adapted combination
of pola-R-CHP with dose-attenuated chemotherapy in the older patient population is ongoing
(ClinicalTrials.gov number, NCT04332822).
Among patients with DLBCL, first-line treatment with the pola-R-CHP combination evaluated in the current trial showed a progressionfree survival benefit over the R-CHOP regimen at
2 years and had a similar safety profile.
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